Sarconesiopsis magellanica (Diptera: Calliphoridae) excretions and secretions have potent antibacterial activity Academic Article

abstract

  • The most important mechanism for combating infection using larval therapy depends on larval excretions and secretions (ES). The present work was aimed at evaluating Sarconesiopsis magellanica (Diptera: Calliphoridae) ES antibacterial activity in six bacterial strains (three Gram-positive and three Gram-negative) and comparing this to the effect of Lucilia sericata-derived ES. Antibacterial activity at 50. μg/mL minimum inhibitory concentration (MIC) was observed for Staphylococcus epidermidis ATCC-12228 and Staphylococcus aureus ATCC-29213 strains, when the turbidimetry test involving S. magellanica ES was used; the rest of the bacterial strains (Staphylococcus aureus ATCC-6538, Pseudomonas aeruginosa ATCC-10145, Pseudomonas aeruginosa ATCC-9027 and Pseudomonas aeruginosa ATCC-27853) were inhibited at a 100. μg/mL MIC. Twice the amount was required to inhibit the aforementioned bacteria with L. sericata-derived ES using this same technique; a similar trend was observed when the agar diffusion method was used instead. Furthermore, when the previously established MIC for each bacterial strain was used, their colonies became reduced following 1-6. h incubation with S. magellanica derived ES, whilst the reduction occurred from 2 to 6. hours with those from L. sericata. Although the MIC for each strain obtained with ciprofloxacin was lower than those established when using either blowfly derived-ES, the gradual reduction of the colonies occurred at a longer incubation time (6. h or more). The results showed that S. magellanica ES antibacterial activity was more potent and effective, compared to that of L. sericata-derived ES. © 2014 Elsevier B.V.

publication date

  • 2014/1/1

keywords

  • Agar
  • Bacteria
  • Ciprofloxacin
  • Diptera
  • Infection
  • Microbial Sensitivity Tests
  • Nephelometry and Turbidimetry
  • Pseudomonas aeruginosa
  • Staphylococcus aureus
  • Staphylococcus epidermidis
  • Therapeutics

International Standard Serial Number (ISSN)

  • 0001-706X

number of pages

  • 7

start page

  • 37

end page

  • 43